The silent predictors: exploring galectin-3 and Irisin's tale in severe COVID-19.
Biomarker discovery
COVID-19 prognosis
Galectin-3
Irisin
SARS-CoV-2 infection
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
27 Oct 2024
27 Oct 2024
Historique:
received:
24
04
2024
accepted:
15
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
This study aimed to evaluate the roles of galectin-3 and irisin as biomarkers in predicting severe outcomes in COVID-19 patients. We analyzed serum levels of galectin-3 and irisin in 59 patients with severe COVID-19 and 30 healthy controls. Elevated galectin-3 levels were associated with increased risks of mortality, need for intensive care, and severe acute respiratory distress syndrome. The optimal cut-off value for galectin-3 was 13.47 ng/ml, with a sensitivity of 72.7% and specificity of 76.6%. Irisin levels did not differ significantly between survivors and non-survivors at admission or on the 3rd day post-admission, but approached significance on the 7th day. These findings suggest that galectin-3 could be a valuable prognostic biomarker for severe COVID-19 outcomes, while irisin's role remains to be clarified in further studies.
Identifiants
pubmed: 39465409
doi: 10.1186/s13104-024-06978-3
pii: 10.1186/s13104-024-06978-3
doi:
Substances chimiques
Fibronectins
0
Biomarkers
0
FNDC5 protein, human
0
Galectin 3
0
LGALS3 protein, human
0
Galectins
0
Blood Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
324Subventions
Organisme : Ministry of Education, Science and Technological Development, Republic of Serbia
ID : 451-03-66/2024-03/200113
Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. COVID-19Weekly Epidemiological Update. Edition 50 Published 27 July 2021. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019? (accessed on 14 March 2024).
Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451–2460. doi: 10.1056/NEJMcp2009575. Epub 2020 May 15. PMID: 32412710.
Napoli C, Benincasa G, Criscuolo C, Faenza M, Liberato C, Rusciano M. Immune reactivity during COVID-19: implications for treatment. Immunol Lett. 2021;231:28–34. https://doi.org/10.1016/j.imlet.2021.01.001 .
doi: 10.1016/j.imlet.2021.01.001
pubmed: 33421440
pmcid: 7787505
Santos A, Magro DO, Evangelista-Poderoso R, Saad MJA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021;13(1):23. https://doi.org/10.1186/s13098-021-00639-2 . PMID: 33648564; PMCID: PMC7919999.
doi: 10.1186/s13098-021-00639-2
pubmed: 33648564
pmcid: 7919999
Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 and diabetes: a bidirectional relationship. Clin Investig Arterioscler. 2021 May-Jun;33(3):151–7. https://doi.org/10.1016/j.arteri.2020.10.001 . English, Spanish.
Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, Mantzoros CS. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324–37. https://doi.org/10.1038/nrendo.2016.221 . Epub 2017 Feb 17. PMID: 28211512; PMCID: PMC5878942.
doi: 10.1038/nrendo.2016.221
pubmed: 28211512
pmcid: 5878942
Zhu W, Sahar NE, Javaid HMA, Pak ES, Liang G, Wang Y, et al. Exercise- Induced Irisin decreases inflammation and improves NAFLD by competitive binding with MD2. Cells. 2021;10:3306. https://doi.org/10.3390/cells10123306 .
doi: 10.3390/cells10123306
pubmed: 34943814
pmcid: 8699279
Liu FT, Stowell SR. The role of galectins in immunity and infection. Nat Rev Immunol. 2023;23(8):479–94. https://doi.org/10.1038/s41577-022-00829-7 . Epub 2023 Jan 16. PMID: 36646848; PMCID: PMC9842223.
doi: 10.1038/s41577-022-00829-7
pubmed: 36646848
Gaughan EE, Quinn TM, Mills A, Bruce AM, Antonelli J, MacKinnon AC, Aslanis V, Li F, O’Connor R, Boz C, Mills R, Emanuel P, Burgess M, Rinaldi G, Valanciute A, Mills B, Scholefield E, Hardisty G, Findlay EG, Parker RA, Norrie J, Dear JW, Akram AR, Koch O, Templeton K, Dockrell DH, Walsh TS, Partridge S, Humphries D, Wang-Jairaj J, Slack RJ, Schambye H, Phung D, Gravelle L, Lindmark B, Shankar-Hari M, Hirani N, Sethi T, Dhaliwal K. An inhaled Galectin-3 inhibitor in COVID-19 pneumonitis: a phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE). Am J Respir Crit Care Med. 2023;207(2):138–49. https://doi.org/10.1164/rccm.202203-0477OC . PMID: 35972987; PMCID: PMC9893334.
doi: 10.1164/rccm.202203-0477OC
pubmed: 35972987
Schroeder JT, Bieneman AP. The S1 subunit of the SARS-CoV-2 spike protein activates human monocytes to produce cytokines linked to COVID-19: relevance to Galectin-3. Front Immunol. 2022;13:831763. https://doi.org/10.3389/fimmu.2022.831763 . PMID: 35392091; PMCID: PMC8982143.
doi: 10.3389/fimmu.2022.831763
pubmed: 35392091
pmcid: 8982143
Gajovic N, Markovic SS, Jurisevic M, Jovanovic M, Arsenijevic N, Mijailovic Z, Jovanovic M, Jovanovic I. Galectin-3 as an important prognostic marker for COVID-19 severity. Sci Rep. 2023;13(1):1460. https://doi.org/10.1038/s41598-023-28797-5 . PMID: 36702907; PMCID: PMC9878495.
doi: 10.1038/s41598-023-28797-5
pubmed: 36702907
pmcid: 9878495
Özcan S, Dönmez E, Yavuz ST, Ziyrek M, İnce O, Küçük HS, Taşdemir ZA, Yılmaz İ, Varol S, Şahin İ, Okuyan E. Prognostic significance of serum galectin-3 in hospitalized patients with COVID-19. Cytokine. 2022;158:155970. https://doi.org/10.1016/j.cyto.2022.155970 . Epub 2022 Jul 28. PMID: 35917725; PMCID: PMC9329148.
doi: 10.1016/j.cyto.2022.155970
pubmed: 35917725
pmcid: 9329148
Cervantes-Alvarez E, la Rosa NL, la Mora MS, Valdez-Sandoval P, Palacios-Jimenez M, Rodriguez-Alvarez F, Vera-Maldonado BI, Aguirre-Aguilar E, Escobar-Valderrama JM, Alanis-Mendizabal J, Méndez-Guerrero O, Tejeda-Dominguez F, Torres-Ruíz J, Gómez-Martín D, Colborn KL, Kershenobich D, Huang CA, Navarro-Alvarez N. Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients. Sci Rep. 2022;12(1):1856. https://doi.org/10.1038/s41598-022-05968-4 . PMID: 35115644; PMCID: PMC8813958.
doi: 10.1038/s41598-022-05968-4
pubmed: 35115644
pmcid: 8813958
Portacci A, Diaferia F, Santomasi C, Dragonieri S, Boniello E, Di Serio F, Carpagnano GE. Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure. Respir Med. 2021;187:106556. https://doi.org/10.1016/j.rmed.2021.106556 . Epub 2021 Aug 4. PMID: 34375925; PMCID: PMC8332745.
doi: 10.1016/j.rmed.2021.106556
pubmed: 34375925
pmcid: 8332745
Garcia-Revilla J, Deierborg T, Venero JL, Boza-Serrano A. Hyperinflammation and fibrosis in severe COVID-19 patients: Galectin-3, a target molecule to consider. Front Immunol. 2020;11:2069. https://doi.org/10.3389/fimmu.2020.02069 .
doi: 10.3389/fimmu.2020.02069
Sigamani A, Mayo KH, Miller MC, Chen-Walden H, Reddy S, Platt D. An oral galectin inhibitor in COVID-19-A Phase II Randomized Controlled Trial. Vaccines (Basel). 2023;11(4):731. https://doi.org/10.3390/vaccines11040731 . PMID: 37112643; PMCID: PMC10140888.
doi: 10.3390/vaccines11040731
pubmed: 37112643
Jover E, Matilla L, Garaikoetxea M, Fernández-Celis A, Muntendam P, Jaisser F, Rossignol P, López-Andrés N. Beneficial effects of Mineralocorticoid receptor pathway blockade against endothelial inflammation Induced by SARS-CoV-2 Spike Protein. Biomedicines. 2021;9(6):639. https://doi.org/10.3390/biomedicines9060639 . PMID: 34204890; PMCID: PMC8228852.
doi: 10.3390/biomedicines9060639
pubmed: 34204890
pmcid: 8228852
de Oliveira M, De Sibio MT, Mathias LS, Rodrigues BM, Sakalem ME, Nogueira CR. Irisin modulates genes associated with severe coronavirus disease (COVID-19) outcome in human subcutaneous adipocytes cell culture. Mol Cell Endocrinol. 2020;515:110917. https://doi.org/10.1016/j.mce.2020.110917 .
doi: 10.1016/j.mce.2020.110917
pubmed: 32593740
pmcid: 7315947
Alves HR, Lomba GSB, Gonçalves-de-Albuquerque CF, Burth P. Irisin, Exercise, and COVID-19. Front Endocrinol (Lausanne). 2022;13:879066. https://doi.org/10.3389/fendo.2022.879066 .
doi: 10.3389/fendo.2022.879066
pubmed: 35784579